Is Sun wooing Lizhu for a larger presence in China?
This article was originally published in Scrip
Even as Sun Pharmaceutical Industries assimilates Takeda-owned URL's generic business (scripintelligence.com, 18 December 2012), there is speculation that the Indian firm may also be keen to build up its branded generics business in China, possibly via an alliance or even a partial acquisition.
You may also be interested in...
Evolving regulations and emerging opportunities appear to have put China firmly on the radar of several frontline Indian firms. Sun Pharma is the latest to join those seeking a larger play in the Asian market.
Advanced Imaging Group Calls For Swifter FDA Approvals For Mobile X-Ray, CT, Ultrasound Devices For COVID-19 Crisis
The Medical Imaging & Technology Alliance (MITA) recently sent a letter to the US FDA recommending steps the agency can take to help the advanced imaging industry quickly respond to the COVID-19 outbreak.
The two-year results from the PARTNER 3 trial showed transcatheter aortic valve replacement with Edwards Lifesciences' Sapien 3 system was statistically non-inferior to surgical valve replacement in low-risk patients. The one-year results from the trial had shown TAVR was superior to surgery in low-risk patients.